Osaka-founded Kringle has increased its round to $15.5m thanks to investors including OUVC in order to fund development of its rare disease treatments.

MicroPort Scientific's cardiovascular technology spinoff secured $130m at a $1.1bn valuation, with the cash to fund R&D, manufacturing and market growth.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Novo has backed automated molecule and material discovery business Kebotix, co-founded by former Harvard University professor Alán Aspuru-Guzik.

The E-Town Biomedical Park-backed biopharmaceutical company, which has some 15 assets in clinical trials, has completed a two-tranche series C round.

Wellness tracking app developer Biobeats has been bought after raising a total of $6.3m in funding from investors including Axa, Samsung and Cantora.

Long-term investors Johnson & Johnson Innovation, JJDC and Pfizer Ventures took part in a round that boosted the radiotherapy developer's overall funding to $264m.

The radiotherapy developer, which is exploiting UChicago research, has now raised $264m in funding overall.

Huma has bought Surrey-founded wellness tracking app developer Biobeats to increase the number of digital biomarkers that underpin its services.